Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
April 18 2024
Results of a large population-based observational cohort study examining the association between weight loss and diabetes remission were recently publ...
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is linked to cognitive dysfunction, hippocampal atrophy and an increased risk for Alzheimer’s disease (AD). Less is known of the role of cortisol levels in the prediction of cognitive decline or in moderating the effect of beta-amyloid in preclinical AD. Researchers evaluated 401 cognitively normal adults enrolled in the Australian Imaging Biomarker & Lifestyle Flagship Study of Ageing (AIBL) who had undergone beta-amyloid neuroimaging at a single time point. Subjects also underwent comprehensive neuropsychological assessment. After 54 months, results showed that higher plasma cortisol levels at baseline were associated with a 2.2 times greater risk of having beta-amyloid presence. Higher cortisol levels were also associated with increased declines in global cognition in general. Compared with older adults with low cortisol and beta-amyloid deposits, those with high cortisol and beta-amyloid showed faster declines in various measures. Researchers concluded that in cognitively normal older adults, high plasma cortisol levels are associated with greater decline in global cognition, and accelerate the effect of beta-amyloid on decline in global cognition, episodic memory and attention over a 54 month period. The results suggest that therapies targeted toward lowering plasma cortisol and beta-amyloid levels may help mitigate cognitive decline in the preclinical phase of AD.
Pietrzak RH, et al. Plasma Cortisol, Amyloid-BETA, and Cognitive Decline in Preclinical Alzheimer’s Disease. (Abstract A 10218) Alzheimer’s Asso International Conf. Toronto 2016 July 22=-28.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment